Genmab — December 2018

[Solsen]

If Genmab want anything with their CD20 x CD3 they need a partner now. Otherwise they could be too late out.

[E_L]

oh, did he, i missed that, interesting.

[E_L]

mmm, yes, that is an interesting thought, they need to be fast now…..

[Solsen]

I belive Roche could be eager to license.

[Solsen]

Yes JW have said as Sukkeralf reffering.

[Sukkeralf]

Jan also mentioned that Roche/Genentech had 3 CD3/CD20 BsAb - two in the clinic and one preclinical. So guess not interested begore Genmab present outstanding data

[Solsen]

I dont think the bite technology is competitive

[Sukkeralf]

Too old - was it regeneron that also had a BCMA-CD3 BsAb at ASH ?

[E_L]

i guess it is too early to expect any data from Genmab´s cd3cd20 presentation tonight?

[Sukkeralf]

Way too early - maybe ASH next year

[Solsen]

If you work with three bsabs at Genentech it certainly dont look like they have found the needle in the haystack

[bibob]

Maybe Genmab have the needle.

[Sukkeralf]

Jan said Its because Its so hard to predict what you exactly need - three is better than one

[Sukkeralf]

But nice data for BsAbs will give more value to Genmabs preclinical and early pipeline as it based on this

[Solsen]

Discontinuation was relative high in Regenerons trial. The silencing of the CD3 arm could be the right way

[Bulder]

Just a detail: It's not the cd3-arm that is silenced. It's the Fc-part.

[Solsen]

Correct

[Solsen]

The data presented at ASH included a total of 68 patients with R/R B-NHL who were treated with REGN1979. These patients had received a median of three prior therapies, including an anti-CD20 therapy. As of September 2018, 14 patients had completed treatment, 13 patients remained on treatment and 41 had discontinued treatment. The most common reason for treatment discontinuation was progressive disease (27 patients).

[Solsen]

2/3 of pts discontinued !

[E_L]

https://twitter.com/DrOmarNadeem/status/1068937605721448448